Boston Scientific accounts are for healthcare professionals only.
Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.
My Boston Scientific account
Access your online applications and manage your customer profile.
Quick Links
Call customer care
Over 80% of people with AFib on blood thinners are open to trying a new treatment to lower their stroke risk.2
The WATCHMAN™ device effectively reduces the risk of stroke—without the risk of bleeding that can come with the long-term use of blood thinners.3,4 This makes left atrial appendage closure (LAAC) therapy an important option for patients with a history or risk of serious bleeding on blood thinners.
Built on the proven safety profile of the WATCHMAN FLX™ LAAC Device, the WATCHMAN FLX Pro is designed to treat more indicated patients with higher procedural efficiency and enhanced safety.
20 yrs
Of innovation and experience
700+
LAAC programs established
150k+
Patients treated
Designed to improve implant success, the WATCHMAN TruSteer Access System optimizes coaxial device positioning in the widest range of left atrial appendage (LAA) anatomies.
The WATCHMAN FLX Pro Device is designed with three first-ever features:
With a 25% increase in device size range, the WATCHMAN FLX Pro unlocks up to 6% growth in the treatable patient population.
Boston Scientific announced positive results from the OPTION Clinical Trial at the AHA Scientific Sessions 2024 on November 16. OPTION is the first randomized, head-to-head study comparing WATCHMAN FLX™ Left Atrial Appendage Closure Device to oral anticoagulants (OACs) (95% dual oral anticoagulants (DOACs) post atrial fibrillation ablation.6
OPTION Three-Year Primary Endpoint Results:
This allowed patients to eliminate continuous medication use, significantly reducing bleeding risk while maintaining stroke protection.
Boston Scientific is dedicated to supporting patients at every step of their journey to WATCHMAN. Our patient campaign identifies, activates, and educates eligible patients about the WATCHMAN Implant as an alternative to blood thinners for managing stroke risk and bleeding worry.
Digital tools and templates are available to help you educate patients and increase local awareness for your WATCHMAN program. Download WATCHMAN Patient Materials and Hospital Media Kit.
WATCHMAN Calibration Program
The WATCHMAN Calibration Program is a team of experts that partner with you to enhance operational efficiency, identify referral trends and opportunities, and improve procedural efficiency to maximize performance.
HAWKEYE™ An online solution to help you facilitate LAAC patient workflow.
HAWKEYE notifies your team of any pre-procedure or post-implant tasks to support program compliance and the best possible patient experience. HAWKEYE helps you understand program performance and patient outcomes, making it easier to optimize operational efficiencies and streamline patient coordination.
LAAC for stroke protection with WATCHMAN FLX Pro Left Atrial Appendage Closure Device is one of the fastest growing procedures in cardiology.
On October 1, 2024, CMS released the final inpatient prospective payment system (IPPS) rule for FY 2025 which approved a new MS-DRG 317 for concomitant intracardiac ablation and left atrial appendage closure procedures. This rule is effective for hospital discharges on or after October 1, 2024.
A dedicated team of health economics professionals can help you understand the economics of your LAAC program at various levels through:
Program economic overview
Our team uses public data to identify current-year reimbursement, historic cost details like LOS, and DRG mix, comparing hospital-specific benchmarks with national, state, and CBSA levels.
Program economic deep-dive
Using customer-specific ICD-10-CM/PCS data, our team analyzes coding, charges, and direct costs of the LAAC program to identify opportunities to improve revenue cycle management, calculate contribution margin, and compare hospital specific performance year-over-year.
References:
1. BSC survey data on file
2. WatchUsNow.com. The Harris Poll online survey. Boston Scientific. SH-574213-AA https://www.watchusnow.com/?page=d75be9d4-ba36-456c-a72d-dc3df07892da. Accessed March 28, 2019
3. Holmes DR Jr, Doshi SK, Kar S, et al. Left atrial appendage closure as an alternative to warfarin for stroke prevention in atrial fibrillation: a patient-level meta-analysis. J Am Coll Cardiol. 2015;65(24):2614-2623.
4. Price MJ, Reddy VY, Valderrábano M, et al. Bleeding outcomes after left atrial appendage closure compared with long-term warfarin. JACC Cardiovasc Interv.2015;8(15):1925-1932.
5. Saliba et al. JACC: Clinical Electrophysiology, May 2023. Bench testing or pre-clinical study results may not necessarily be indicative of clinical performance. N=12 in a pre-clinical canine study
6. Thermal Afib ablation only
